Hwail Pharmaceutical Co.Ltd Total Liabilities
Hwail Pharmaceutical Co.Ltd total liabilities. Based on the latest financial reports, Hwail Pharmaceutical Co.Ltd (061250) has total liabilities worth ₩5.29 Billion KRW (≈ $3.58 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Hwail Pharmaceutical Co.Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hwail Pharmaceutical Co.Ltd (2011–2024)
Total liabilities of Hwail Pharmaceutical Co.Ltd from 2011 to 2024. This chart illustrates how Hwail Pharmaceutical Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 061250 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Hwail Pharmaceutical Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Hwail Pharmaceutical Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Microtek International Inc
TW:2305
|
Taiwan | NT$569.67 Million |
|
Career Technology MFG Co Ltd
TW:6153
|
Taiwan | NT$6.91 Billion |
|
Wuhan Nusun Landscape Co Ltd
SHE:300536
|
China | CN¥459.92 Million |
|
Gevo Inc
NASDAQ:GEVO
|
USA | $209.76 Million |
|
Carindale Property Trust
AU:CDP
|
Australia | AU$232.30 Million |
|
SNTEnergy Co Ltd
KO:100840
|
Korea | ₩184.55 Billion |
|
D. Boral Acquisition I Corp. Class A Ordinary Shares
NASDAQ:DBCA
|
USA | $71.28K |
|
Jerusalem
TA:JBNK
|
Israel | ILA21.45 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Hwail Pharmaceutical Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 061250 current and non-current assets.
Liquidity & Leverage Metrics
Hwail Pharmaceutical Co.Ltd Total Liabilities Ratios Explained
Hwail Pharmaceutical Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 25.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hwail Pharmaceutical Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hwail Pharmaceutical Co.Ltd (2011–2024)
The table below shows the annual total liabilities of Hwail Pharmaceutical Co.Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩12.19 Billion ≈ $8.26 Million |
+5.60% |
| 2023-12-31 | ₩11.55 Billion ≈ $7.83 Million |
+15.20% |
| 2022-12-31 | ₩10.02 Billion ≈ $6.79 Million |
-19.74% |
| 2021-12-31 | ₩12.49 Billion ≈ $8.46 Million |
-2.55% |
| 2020-12-31 | ₩12.82 Billion ≈ $8.69 Million |
-35.82% |
| 2019-12-31 | ₩19.97 Billion ≈ $13.53 Million |
-9.88% |
| 2018-12-31 | ₩22.16 Billion ≈ $15.02 Million |
-13.86% |
| 2017-12-31 | ₩25.72 Billion ≈ $17.43 Million |
-10.54% |
| 2016-12-31 | ₩28.76 Billion ≈ $19.49 Million |
-30.42% |
| 2015-12-31 | ₩41.33 Billion ≈ $28.01 Million |
+22.08% |
| 2014-12-31 | ₩33.85 Billion ≈ $22.94 Million |
-7.79% |
| 2013-12-31 | ₩36.71 Billion ≈ $24.88 Million |
+18.76% |
| 2012-12-31 | ₩30.92 Billion ≈ $20.95 Million |
+5.72% |
| 2011-12-31 | ₩29.24 Billion ≈ $19.82 Million |
-- |
About Hwail Pharmaceutical Co.Ltd
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.